Case Report

**PARS2-associated mitochondrial disease: A case report of a patient with prolonged survival and literature review**

Mohammed A. Almuqbil\(^a,b,c\), Hilary J. Vernon\(^a\), Marcia Ferguson\(^d\), Antonie D. Kline\(^d\)

\(^a\) McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.
\(^b\) Division of Pediatric Neurology, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
\(^c\) King Abdullah International Medical Research Center, King Abdullah Specialist Children’s Hospital – Ministry of National Guard, Riyadh, Saudi Arabia.
\(^d\) Harvey Institute for Human Genetics, Greater Baltimore Medical Center, Baltimore, MD, USA.

**ARTICLE INFO**

**Keywords:**
- Aminoacyl-tRNA synthetases
- PARS2
- Exome sequencing
- Mitochondrial

**ABSTRACT**

Biallelic pathogenic variants in mitochondrial aminoacyl-tRNA synthetase (mt-aaRS) PARS2 are associated with mitochondrial cytopathy. Here, we report the tenth case of an individual with biallelic PARS2 pathogenic variants, detected by exome sequencing (ES), and a literature review of ten cases of PARS2 mutations. Our patient displayed symptoms and clinical and laboratory findings similar to those reported previously with normal lactate levels. These symptoms included seizure disorder (which was managed with antiepileptics), developmental delay, and progressive cardiomyopathy which manifested at 19 years of age. The patient received a vitamin regimen including antioxidants as part of his treatment regimen. While further studies are required to conclusively establish the beneficial role of vitamin and cofactor administration on the mitochondria in PARS2-associated mitochondrial disease, these factors may have delayed the onset of cardiomyopathy.

1. Introduction

Mitochondrial aminoacyl tRNA synthetases (aaRSs) are essential for mitochondrial protein biosynthesis and oxidative phosphorylation \([1–6]\). Nineteen nuclear genes encode the aaRSs, including prolyl-tRNA synthetase 2, or PARS2, which charges mitochondrial prolyl-tRNA with its cognate amino acid, proline.

Biallelic pathogenic PARS2 variants are associated with early infantile epileptic encephalopathy (EIEE75, MIM 618437), a multi-system mitochondrial disorder. Clinical features previously observed in nine individuals with PARS2 deficiency include microcephaly, hypotonia, seizures, intellectual disability, structural brain abnormalities, and other systemic findings including lactic acidemia. All patients generally have similar characteristics and symptoms, with most dying during the first 10 years of age \([6–11]\) (Table 1).

Herein, we report the case of an individual with heterozygous pathogenic PARS2 variants diagnosed through exome sequencing. Unlike most previous cases, chronic lactic acidemia was not present, and cardiomyopathy did not occur until adulthood (19 years). He died of cardiac failure at 21 years of age. To our knowledge, this patient had the longest lifespan with this disorder.

2. Case presentation

**Clinical Course.** This male patient presented initially at eight months with epilepsy, global delays, and recurrent respiratory infections. Electroencephalography (EEG) revealed high-amplitude, posteriorly accentuated spikes consistent with hypsarrhythmia. Initial seizures were intractable, despite antiepileptics, but were gradually controlled with adrenocorticotropic hormone (ACTH). Biochemical analysis revealed a single serum lactate elevation during infancy (which was normal on follow-up evaluations), normal amino acid levels in plasma and cerebrospinal fluid, and normal urine organic acids. Peroxisomal studies yielded normal results. Brain MRI revealed frontal and anterior parietal atrophy with signal changes involving the caudate, lentiform nuclei, and bilateral thalami. Karyotype was normal and fluorescence in situ hybridization revealed negative results for Angelman syndrome. Initial ophthalmologic and audiologic examinations and mitochondrial enzyme assays in fibroblasts revealed normal findings. Because an older deceased sibling had a similar presentation, an unknown mitochondrial disorder was speculated and an antioxidant vitamin mixture including vitamins C, B1, B2, B3 (100 mg twice daily), and E (200 mg twice daily), Q10, lipoic acid, and levocarnitine (250 mg thrice daily) was
| Sex   | Family history | Longevity | Clinical findings | EEG findings | Lactate levels | Muscle/Alanine aminotransferase | Genotype (ES)                                                                 |
|-------|----------------|-----------|------------------|--------------|---------------|-------------------------------|----------------------------------------------------------------------------|
| Male  | Eldest brother in same phenotype | Died at age of 16 years | Cerebral atrophy, bifrontal subdural hematoma. | Hypsarrhythmia, multifocal spikes, sharp waves with a symmetric background pattern | Elevated lactate levels, CSF lactate level high | Elevated (serum and CSF) | Maternally-inherited c.283G > A (p.Val95Ile) and paternally-inherited 1091C > G (p.Pro364Arg) |
| Female | Not mentioned | Died under 2 years | Not mentioned | Normal | Not done | Normal | Compound heterozygous variants: maternally-inherited c.201C > A (p.Tyr67His) and paternally-inherited 1685C > T (p.Ile562Met) |

(continued on next page)
prescribed. Other medications included levetiracetam to control seizures. Throughout childhood, his cardiovascular function was stable, presenting normal findings on echocardiography, and only several illnesses requiring hospitalizations for respiratory distress and occasionally increased seizure frequency. Surgeries included posterior spinal fusion for scoliosis and surgical release of bilateral knee contractures. He had global developmental delay throughout childhood, but no developmental regression.

At 19 years, the patient presented with viral illness and dehydration, and echocardiography showed mildly depressed cardiac function with left ventricular ejection fraction of 50%; low-dose lisinopril was administered. Physical examination revealed normal height and weight, microcephaly (circumference below the second percentile), with flattened occiput, mildly dysmorphic facial features including synophrys, malar hypoplasia, and mild prognathism, chin crease, and diffuse hypertonia (Fig. 1). He was nonverbal but responded to simple commands, interacted with his family, and was independently ambulatory.

Two years later, echocardiography revealed severe cardiac failure with a left ventricular ejection fraction of 20%. Aspirin, digoxin, carvedilol, and lisinopril were prescribed at low doses. He was readmitted twice with respiratory distress and suspected viral illness and was then discharged to home hospice and died of cardiac failure at 21 years of age.

**Family History.** The patient’s eldest brother presented at 4 months with infantile spasms, which progressed to seizures, nystagmus, and profound intellectual disability. Brain magnetic resonance imaging (MRI) revealed cerebral atrophy. At 5 years, he died from severe cardiomyopathy and lactic acidosis. An underlying mitochondrial disease was suspected. Muscle biopsy indicated variations in myofiber size, reduced activity of multiple respiratory chain enzymes, and normal electron microscopic findings. Cytochrome c oxidase activity ranged from 0.04 (control 0.52 ± 0.17 in the brain) to 0.64 (2.8 ± 0.52). Cytochrome c oxidase staining revealed equivocal results. Increased citrate synthase activity was consistent with mitochondrial proliferation. Autopsy revealed frontal cerebral cortex atrophy and normal cortical mitochondria. The patient had another healthy older brother.

**Molecular Findings.** Written consent was obtained from the family for trio-exome sequencing. The patient harbored compound heterozygous variants of uncertain significance: c.1091C > G (p.P364R), inherited paternally, and c.283 G > A (p.V95I), inherited maternally. This exact genotype has been reported recently by Al Balushi et al. [11]. Monoallelic P364R in PARS2 was reported in four different individuals with congenital microcephaly, early infantile epileptic encephalopathy, dilated cardiomyopathy, and Leigh syndrome-like disease [8,9]. In silico analyses predicted deleterious effects. V95I was previously reported in four individuals with early infantile epileptic encephalopathy and hypertonia [6,7]. It has also been reported in the homozygous state by Maddirevula et al. [12]. The c.1091C > G (p.P364R) allele has been found in 295 out of 281,922 alleles, whereas the c.283 G > A (p.V95I) was found in 31 out of 282,762 alleles in the GnomAD database. However, neither were found in the homozygous state in GnomAD.

### Table 1 (continued)

| Our Case | Our Case | Pronicka et al. [9] | Minaguchi et al. [6] | Girand et al. [8] | Yin et al. [7] | Nishida et al. [10] (1st case report of PARS2 mutation) | Salou et al. [11] | Al Balushi et al. [11] |
|----------|----------|---------------------|---------------------|-------------------|--------------|------------------------------------------------|-----------------|-----------------------|
| optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” | optic atrophy, mitochondrial “cocktail” |
| M. A. Almuqbil, et al. | Molecular Genetics and Metabolism Reports 24 (2020) 100613 | 3 |

3. Discussion

Herein, we report the oldest documented patient harboring biallelic PARS2 pathogenic variants with cardiac function preserved until shortly before death, who had the longest lifespan in this condition reported thus far.

**PARS2** mutations are rare, previously reported in only nine patients (Table 1). Our patient harbored one mutation (P364R) in common with the eldest of three affected siblings (Table 1). The elder brother and sister both died at 8.5 years of age [8]. Two sisters harboring PARS2 mutations [7] shared one pathogenic variant with our patient, c.283 G > A (p.V95I) (Table 1). The younger sister died at 4 months, while the elder sibling was 3 years at the time of publication. None of these patients were treated with antioxidants. All had elevated lactate
levels, unlike our patient. Though our patient periodically required hospitalization, he survived for two decades. Among supportive therapies, he received a regimen of antioxidant supplements targeting mitochondrial dysfunction since infancy. Furthermore, he had an affected older brother, who received no treatment and died during early childhood from cardiac failure.

Some treatment strategies for mitochondrial diseases involve bypassing mitochondrial functions, including natural substances directly involved in ATP production, such as creatine (when the ATP demand exceeds the mitochondrial supply, creatine releases phosphate to increase ATP production), carnitine (improves ATP efficiency by clearing the toxic byproducts of ATP synthesis and facilitating ATP production by importing fuel molecules in the mitochondria), and coenzyme Q10 (essential for mitochondrial respiration) [13].

Mitochondrial cytopathies are associated with reduced transduction of aerobic energy (decreased ATP synthesis), increased oxidative stress, apoptosis, and necrosis. Theoretically, combinations of specific nutraceuticals bypass deficiencies in mitochondrial respiration, potentially providing an alternate energy source [13,14]. A previous randomized placebo-controlled trial involving patients with mitochondrial cytopathies reported that creatine monohydrate, alpha lipoic acid, and coenzyme q10 reduced lactate levels and oxidative stress (as indicated by its markers) [13].

While numerous factors could have contributed to significant differences in disease severity between our patient and his sibling, we hypothesize that antioxidant supplementation may have delayed the onset of cardiomyopathy and contributed to normal lactate levels and oxidative stress (as indicated by its markers) [13].

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics approval

Not applicable.

Patient consent statement

The patient’s family provided informed consent for the publication of this case report.

Declaration of Competing Interest

The authors disclose no conflict of interest.

Acknowledgements

We appreciate the support from this family. We also appreciate the advice and recommendations of Richard Kelley, M.D., Ph.D. regarding the metabolic supplementation.

References

[1] T. Suzuki, A. Nagao, T. Suzuki, Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases, Annu. Rev. Genet. 45 (2011) 299–329, https://doi.org/10.1146/annurev-genet-110410-122531.
[2] S. Havrylenko, M. Mirande, Aminoacyl-tRNA synthetase complexes in evolution, Int. J. Mol. Sci. 16 (2015) 6571–6594, https://doi.org/10.3390/ijms16036571.
[3] C. Fraenckl, K. Musser-Forysth, S.A. Martinis, Aminoacyl-tRNA synthetases in biology and disease: new evidence for structural and functional diversity in an ancient family of enzymes, RNA 3 (1997) 954–960.
[4] Z. Zhu, X. Wang, Significance of mitochondria DNA mutations in diseases, Adv. Exp. Med. Biol. (2017) 219–230, https://doi.org/10.1007/978-981-10-6674-0_15.
[5] E. Ylikallio, A. Suomalainen, Mechanisms of mitochondrial diseases, Ann. Med. 44 (2012) 41–59, https://doi.org/10.3109/07853890.2011.598547.
[6] T. Mizuguchi, M. Nakashima, M. Kato, K. Yamada, T. Oka, N. Ekhilevitch, et al., PARS2 and NARS2 mutations in infantile-onset neurodegenerative disorder, J. Hum. Genet. 62 (2017) 525–529, https://doi.org/10.1038/jhg.2016.153.
[7] X. Yin, B. Tang, X. Mao, J. Peng, S. Zeng, Y. Wang, et al., The genotypic and phenotypic spectrum of PARS2-related infantile-onset encephalopathy, J. Hum. Genet. 63 (2018) 971–980, https://doi.org/10.1038/s41005-018-0478-z.
[8] E. Giara, D. Roki, M. Luszniewski, H. Morzerowska, E. Herkiewicz, M. Beksińska-Figotowska, et al., Clinical and molecular characteristics of newly reported mitochondrial disease entity caused by biallelic PARS2 mutations, J. Hum. Genet. 63 (2018) 473–485, https://doi.org/10.1038/s41005-017-0401-z.
[9] E. Pronicka, D. Piekutowska-Abramczuk, E. Giara, J. Trubicka, D. Roki, A. Karkucińska-Wieczkowska, et al., New perspective in diagnostics of mitochondrial...
disorders: two years’ experience with whole-exome sequencing at a national pediatric Centre, J. Transl. Med. 14 (2016) 174, https://doi.org/10.1186/s12967-016-0930-9.

[10] K. Sofou, G. Kollberg, M. Holmström, M. Dívila, N. Darin, C.M. Gustafsson, et al., Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome, Mol. Genet. Genom. Med. 3 (2015) 59–68, https://doi.org/10.1002/mgg3.115.

[11] A. Al Balushi, D. Matviychuk, R. Jobling, G.S. Salomons, S. Blaser, S. Mercimek-Andrews, Phenotypes and genotypes of mitochondrial aminoacyl-tRNA synthetase deficiencies from a single neurometabolic clinic, JIMD Rep. 51 (2020) 3–10, https://doi.org/10.1002/jmd2.12079.

[12] S. Maddirevula, F. Alzahrani, M. Al-Owain, M.A. Al Muhaizea, H.R. Kayyali, A. AlHashem, et al., Autozygome and high throughput confirmation of disease genes candidacy, Genet. Med. 21 (2019) 736–742, https://doi.org/10.1038/s41436-018-0138-x.

[13] M.C. Rodriguez, J.R. MacDonald, D.J. Mahoney, G. Parise, M.F. Beal, M.A. Tarnopolsky, Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders, Muscle Nerve 35 (2007) 235–242, https://doi.org/10.1002/mus.20688.

[14] M.A. Tarnopolsky, The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies, Adv. Drug Deliv. Rev. 60 (2008) 1561–1567, https://doi.org/10.1016/j.addr.2008.05.001.